ResearcherUniversity of TorontoNo recent work listed

Vanessa Sarah Arciero

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5045623415. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2022: 1 paper

Papers 1

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac047 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ambica Parmar · 1 shared paper, 2022 · strength 0.13
- Paper Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pan… DOI 10.1093/jncics/pkac047 ↗
Wei Fang Dai · 1 shared paper, 2022 · strength 0.13
- Paper Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pan… DOI 10.1093/jncics/pkac047 ↗
Kelvin Chan · 1 shared paper, 2022 · strength 0.13
- Paper Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pan… DOI 10.1093/jncics/pkac047 ↗
Michael Jonathon Raphael · 1 shared paper, 2022 · strength 0.13
- Paper Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pan… DOI 10.1093/jncics/pkac047 ↗
Nicole Mittmann · 1 shared paper, 2022 · strength 0.13
- Paper Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pan… DOI 10.1093/jncics/pkac047 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.